Cargando…

Aberrant Expression of miR-592 Is Associated with Prognosis and Progression of Renal Cell Carcinoma

PURPOSE: MicroRNAs have recently reported playing a vital role in the development of cancers. However, the role of miR-592 in renal cell carcinoma (RCC) has not been explored. In this study, the potential role of miR-592 was investigated in RCC. PATIENTS AND METHODS: The expression of miR-592 was ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Xianbao, Shen, Jingang, Guo, Zhen, Kong, Lingwei, Zhou, Guangchun, Ning, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927226/
https://www.ncbi.nlm.nih.gov/pubmed/31908489
http://dx.doi.org/10.2147/OTT.S227834
Descripción
Sumario:PURPOSE: MicroRNAs have recently reported playing a vital role in the development of cancers. However, the role of miR-592 in renal cell carcinoma (RCC) has not been explored. In this study, the potential role of miR-592 was investigated in RCC. PATIENTS AND METHODS: The expression of miR-592 was evaluated in RCC tissues and cell lines using qRT-PCR assays. The Kaplan-Meier analysis and Cox proportional hazards model analysis was used to analyze the prognostic value of miR-592 in RCC. The effects of miR-592 on cell proliferation, migration, and invasion were determined by cell counting kit-8 (CCK-8) and Transwell assays in vitro. RESULTS: The results showed that miR-592 was significantly increased both in RCC tissues and cell lines. Overexpression of miR-592 was significantly associated with lymph node metastasis, TNM stage, and poor overall survival. And functional studies in two RCC cell lines (786-O and Caki-1) have shown that overexpression of miR-592 promoted cell proliferation, migration, and invasion, while silence of miR-592 inhibited cell proliferation, migration, and invasion. SPRY2 was a direct target of miR-592. CONCLUSION: Overall, overexpression of miR-592 may be a prognostic biomarker and therapeutic strategy for patients with RCC, which is correlated with the progression of RCC.